Work

Preeclampsia Risk in Obese Pregnant Women without Diabetes Mellitus: a Meta-Analysis Comparing Metformin versus Control Group

Year: 2026
Type: article
Abstract: Objective: To evaluate the impact of metformin on reducing the risk of pre-eclampsia in obese pregnant women without diabetes. Sources of Data: Following PRISMA guidelines, Scopus, Embase, PubMed (MEDLINE), Cochrane Database of Systematic Reviews, LILACS, SciElo, and Web of Science were searched for articles published between 2014 and April 2024. Search terms: ("Metformin" OR "Biguanide" OR "Glucophage" OR "dimethylbiguanide") AND ("pre-eclampsia" OR "preeclampsia") AND ("obese pregnant women" OR "obesity in pregnancy" OR "maternal obesity" OR "pregnancy" OR "obesity"). Study Selection: From 2022 studies identified, three randomized controlled trials comparing metformin with placebo or standard care in obese pregnant women without diabetes were included. Primary outcomes were pre-eclampsia incidence; secondary outcomes included gestational hypertension, gestational diabetes, preterm birth, cesarean delivery, postpartum hemorrhage, and NICU admission. Data collection: statistics. Data Synthesis: =0%). Metformin alone may not effectively prevent PE in these women, but efficacy could improve with lifestyle modifications. Study heterogeneity highlights the need for larger, rigorous trials. Conclusions: CRD42024611538.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7204159689
FWCI:
Cites: 18
Cited by:
Related to: 8